Harvard stem cell researchers and scientists at the University of Cambridge in the United Kingdom have found that the age-related degeneration in conditions such as multiple sclerosis (MS) may be reversible.... Read more about Age-related effects of MS may prove reversible

The prime mandate of the Center for Human Cell Therapy (CHCT) is to provide resources to investigators to facilitate bench-to-bedside development of novel cellular therapies for the treatment of human diseases (www.chct.org). CHCT is part of the Production Assistance in Cellular Therapies (PACT) program of the National Heart Lung and Blood Disease Institute (NHLBI). For more information on the PACT program please visit www.pactgroup.net.

Successful clinical cell therapies require the translation of laboratory-based techniques into standard operating procedures that follow...

Overview:
The Harvard Stem Cell Institute (HSCI) is now accepting applications for one (1) Post-doctoral fellow to be funded by the HSCI’s NIH Training Grant.... Read more about 2012 call for postdoctoral trainee applications

Overview:
The Harvard Stem Cell Institute (HSCI) is now accepting applications for two (2) Graduate student fellows to be funded by the HSCI’s NIH Training Grant.... Read more about 2012 call for graduate student trainee applications

The Harvard Stem Cell Institute (HSCI) Translational Program invites applications for Pilot Grant funding for 2012. The purpose of this funding program is to provide resources for proof-of-concept, preclinical research studies ultimately aimed at therapeutic clinical evaluation in humans to treat pediatric and adult disease.  These pilot grants are intended to foster the discovery phase of translational/pre-clinical research, in which possible therapeutic cellular products and their mechanism of action are explored in relevant animal and/or in vitro model systems.... Read more about 2012 HSCI call for proposals – translational program pilot grants

Application deadline:  Thursday, May 3, 2012

The Harvard Stem Cell Institute (HSCI) Cardiovascular Program invites applications for Pilot Grants for 2012. The purpose of this funding program is to provide resources for research in cardiovascular disease with the goal of developing new therapeutic strategies. As such, a critical component is the translatability of the research project. This may take many forms, and does not require human subjects research; however, thought should be given to how funds will be best used to ultimately bring new therapies or...

Application deadline:  Tuesday, May 1, 2012

The Harvard Stem Cell Institute (HSCI) invites applications for Pilot Grant funding for 2012 under the NIH-funded P01 grant "Dissecting the establishment and regulation of human pluripotency" (PI Alexander Meissner, Harvard Department of Stem Cell and Regenerative Biology). The purpose of this funding program is to provide resources for proof-of-concept studies. These pilot grants are intended to increase our understanding of the basic biology of human pluripotent cells and their utility for translational...

Application deadline:  Friday, May 25, 2012... Read more about 2012 HSCI call for proposals – Diabetes Program pilot grants in the area of type 1 diabetes (T1D)

Harvard stem cell researchers at Massachusetts General Hospital (MGH) have taken a critical step toward discovering in the relatively near future a drug to control cystic fibrosis (CF), a fatal lung disease that claims about 500 lives each year, with 1,000 new cases diagnosed annually.... Read more about Big advance against cystic fibrosis

Call for 2012 Nominations: Deadline June 29, 2012... Read more about 2012 HSCI call for nominations - Sternlicht awards for graduate students

A portfolio of small molecules and biologics has been licensed by Harvard University and the Howard Hughes Medical Institute from the laboratory of Harvard Stem Cell Institute Co-Director Doug Melton, co-chair of Harvard’s Department of Stem Cell and Regenerative Biology, to the German biotech firm Evotec and international giant Janssen Pharmaceuticals, a Johnson & Johnson company, as the central focus of a new program to pursue treatments and cures for diabetes.

“Our collaboration with Doug Melton’s laboratory has been extremely successful on multiple levels,” said Evotec...

A nationwide consortium of scientists at 20 institutions, led by a principal faculty member at the Harvard Stem Cell Institute (HSCI), has used stem cells to take a major step toward developing personalized medicine to treat Parkinson’s disease.... Read more about Study uses stem cells to study variants of Parkinson’s disease

SUBMISSION DEADLINE: 
Thursday, November 15, 2012 - 5:00 p.m. EST

The Harvard Stem Cell Institute (HSCI) Kidney Program invites applications for Pilot Grant funding for 2013. The purpose of this funding program is to provide resources for research in adult kidney disease with the goal of developing new therapeutic strategies. As such, a critical component is the translatability of the research project. This may take many forms, and does not require human subjects research, however thought should be given as to how funds will be utilized to ultimately bring...

SUBMISSION DEADLINES:
Letter of Intent: Friday, December 14, 2012 (5:00 p.m. EST)
Application:  Friday, February 1, 2013 (5:00 p.m. EST)

The Harvard Stem Cell Institute (HSCI) Cancer Program is now accepting applications for 2013 pilot grants. The purpose of this funding program is to provide resources for innovative projects by investigators in the field of cancer stem cell biology. This funding is for groundbreaking, innovative, high-impact research projects in the application of mathematical approaches to cancer stem cell biology....